Well Lead Med Co Ltd Cash Flow Conversion Efficiency
Well Lead Med Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Well Lead Med Co Ltd (603309) has a cash flow conversion efficiency ratio of 0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥126.26 Million ≈ $18.48 Million USD) by net assets (CN¥1.95 Billion ≈ $284.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Well Lead Med Co Ltd (2011–2025)
Cash flow conversion efficiency of Well Lead Med Co Ltd from 2011 to 2025. This chart illustrates how Well Lead Med Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Well Lead Med Co Ltd stock quote for real-time trading data and today's change.
Well Lead Med Co Ltd Cash Flow Conversion Ratio Explained
Well Lead Med Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Well Lead Med Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Well Lead Med Co Ltd ranked by their cash flow conversion efficiency. Also see market cap of Well Lead Med Co Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tae Kwang Corporation
KQ:023160
|
0.012x |
|
Fujian Cement Inc
SHG:600802
|
-0.135x |
|
Brainsway Ltd
NASDAQ:BWAY
|
0.080x |
|
Cerus Corporation
NASDAQ:CERS
|
-0.045x |
|
I-Mab
NASDAQ:IMAB
|
0.007x |
|
Oxiquim S.A
SN:OXIQUIM
|
0.051x |
|
Hankook Shell Oil
KO:002960
|
0.065x |
|
Jilin University Zhengyuan Info Tech
SHE:003029
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Well Lead Med Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Well Lead Med Co Ltd from 2011 to 2025. Review 603309 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.78 Billion ≈ $259.96 Million |
CN¥330.26 Million ≈ $48.33 Million |
0.186x | +15.52% |
| 2024-12-31 | CN¥1.90 Billion ≈ $278.48 Million |
CN¥306.26 Million ≈ $44.82 Million |
0.161x | +26.59% |
| 2023-12-31 | CN¥1.84 Billion ≈ $268.80 Million |
CN¥233.51 Million ≈ $34.17 Million |
0.127x | -43.45% |
| 2022-12-31 | CN¥1.74 Billion ≈ $254.58 Million |
CN¥391.13 Million ≈ $57.23 Million |
0.225x | +91.04% |
| 2021-12-31 | CN¥1.59 Billion ≈ $232.89 Million |
CN¥187.28 Million ≈ $27.41 Million |
0.118x | -41.07% |
| 2020-12-31 | CN¥1.14 Billion ≈ $167.40 Million |
CN¥228.44 Million ≈ $33.43 Million |
0.200x | +15.76% |
| 2019-12-31 | CN¥1.04 Billion ≈ $151.66 Million |
CN¥178.79 Million ≈ $26.16 Million |
0.173x | +80.42% |
| 2018-12-31 | CN¥940.07 Million ≈ $137.56 Million |
CN¥89.89 Million ≈ $13.15 Million |
0.096x | +15.77% |
| 2017-12-31 | CN¥900.07 Million ≈ $131.71 Million |
CN¥74.34 Million ≈ $10.88 Million |
0.083x | -16.45% |
| 2016-12-31 | CN¥863.31 Million ≈ $126.33 Million |
CN¥85.35 Million ≈ $12.49 Million |
0.099x | -5.51% |
| 2015-12-31 | CN¥778.65 Million ≈ $113.94 Million |
CN¥81.47 Million ≈ $11.92 Million |
0.105x | -63.92% |
| 2014-12-31 | CN¥370.18 Million ≈ $54.17 Million |
CN¥107.34 Million ≈ $15.71 Million |
0.290x | +20.35% |
| 2013-12-31 | CN¥302.37 Million ≈ $44.25 Million |
CN¥72.85 Million ≈ $10.66 Million |
0.241x | -27.81% |
| 2012-12-31 | CN¥249.37 Million ≈ $36.49 Million |
CN¥83.23 Million ≈ $12.18 Million |
0.334x | +46.46% |
| 2011-12-31 | CN¥193.41 Million ≈ $28.30 Million |
CN¥44.08 Million ≈ $6.45 Million |
0.228x | -- |
About Well Lead Med Co Ltd
Well Lead Medical Co., Ltd. engages in the development, production, and sale of medical devices in urology, endourology, anaesthesia, respiratory, hemodialysis, and pain management areas worldwide. It provides urology products, including Foley catheter, Nelaton catheters, urine collection products, and accessories; endourology products, such as the ClearPetra family system, ureterorenoscope, guid… Read more